-
Involved-filed radiotherapy for advanced Hodgkin's lymphomaAleman, Berthe M. P. ...BACKGROUND The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. METHODS We randomly assigned patients with previously untreated stage III or IV ... Hodgkin's lymphoma who werein complete remission after hybrid chemotherapy with mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine(MOPP-ABV) to receive either no further treatment or involved-fieldradiotherapy. Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy to all initially involved extranodal sites. Patients in partial remission were treated with 30 Gy to nodal areas and 18 to 24 Gy to extranodal sites. RESULTS Of 739 patients, 421 had a complete remission; 161 of these patients were assigned to no further treatment, and 172 to involved-field radiotherapy. The median follow-up was 79months. The five-year event-free survival rate was 84 percent in the group that did not receive radiotherapy and 79 percent in the group that received involved-field radiotherapy (P=0.35). The five-year overall survival rates were 91 and 85 percent, respectively (P=0.07). Among the 250 patients in partial remission after chemotherapy, the five-year event-free and overall survival rates were 79 and 87 percent, respectively CONCLUSIONS Involved-fieldradiotherapy did not improve the outcome in patients with advanced stage Hodgkin's lymphoma who had a complete remission after MOPP-ABV chemotherapy. Radiotherapy may benefit patients with a partial response after chemotherapy.Vir: The New England journal of medicine. - ISSN 0028-4793 (Letn. 348, št. 24, 2003, str. 2396-2406)Vrsta gradiva - članek, sestavni delLeto - 2003Jezik - angleškiCOBISS.SI-ID - 17401817
Avtor
Aleman, Berthe M. P. |
Tomšič, Radka |
Vovk, Marjeta
Teme
Hodgkin's Disease |
Radiotherapy |
Pathology |
Drug Therapy |
Antineoplastic Agents, Combined |
Bleomycin |
Administration And Dosage |
Doxorubicin |
Administration And Dosage |
Mechlorethamine |
Administration And Dosage |
Age Factors |
Sex Factors |
Combined Modality Therapy |
Neoplasm Staging |
Neoplasms, Second Primary |
Prednisone |
Administration And Dosage |
Procarbazine |
Administration And Dosage |
Remission Induction |
Vincristine |
Administration And Dosage |
Vinblastine |
Administration And Dosage |
Survival Analysis |
Antineoplastiki sestavljeni |
Bleomicin |
Doksorubicin |
Mekloretamin |
Kombinirani način zdravljenja |
Novotvorba, stadij |
Novotvorbe, druge primarne |
Prednizon |
Preživetje, analiza |
Prokarbazin |
Spolni faktorji |
Starostni faktorji |
Vinblastin |
Vinkristin |
Zboljšanje, vzpodbuditev
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Aleman, Berthe M. P. | ![]() |
Tomšič, Radka | 15829 |
Vovk, Marjeta | 09426 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.